ECSP055804A - Composición farmacéutica - Google Patents

Composición farmacéutica

Info

Publication number
ECSP055804A
ECSP055804A EC2005005804A ECSP055804A ECSP055804A EC SP055804 A ECSP055804 A EC SP055804A EC 2005005804 A EC2005005804 A EC 2005005804A EC SP055804 A ECSP055804 A EC SP055804A EC SP055804 A ECSP055804 A EC SP055804A
Authority
EC
Ecuador
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
functional derivative
physiologically functional
Prior art date
Application number
EC2005005804A
Other languages
English (en)
Inventor
Franz Birke
Hans Michael Jennewein
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP055804A publication Critical patent/ECSP055804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El invento se refiere a una formulación farmacéutica que comprende un agente antagonista de LTB4 que tiene un grupo hidroxi y un grupo benzamidino, o un tautómero, una sal farmacéuticamente aceptable, un solvato o un derivado fisiológicamente funcional del mismo, en particular un compuesto de fórmula (I) en el que R y A son como se han definido en las reivindicaciones, o un tautómero, una sal farmacéuticamente aceptable, un solvato o un derivado fisiológicamente funcional del mismo (1) y por lo menos un agente inhibidor de ciclooxigenasa-2, un agente inhibidor de cox1/2 combinado, o una sal farmacéuticamente aceptable, un solvato o un derivado fisiológicamente funcional del mismo (2), y un vehículo o excipiente farmacéuticamente aceptable, y opcionalmente uno o más de otros ingredientes terapéuticos.
EC2005005804A 2002-11-26 2005-05-19 Composición farmacéutica ECSP055804A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026223 2002-11-26

Publications (1)

Publication Number Publication Date
ECSP055804A true ECSP055804A (es) 2005-08-11

Family

ID=32337995

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005804A ECSP055804A (es) 2002-11-26 2005-05-19 Composición farmacéutica

Country Status (23)

Country Link
US (1) US20040116516A1 (es)
EP (1) EP1572179B1 (es)
JP (1) JP2006508992A (es)
KR (1) KR20050086820A (es)
CN (1) CN1717228A (es)
AT (1) ATE355055T1 (es)
AU (1) AU2003298121A1 (es)
BR (1) BR0316486A (es)
CA (1) CA2506948A1 (es)
CO (1) CO5580753A2 (es)
DE (1) DE60312215T2 (es)
EA (1) EA200500860A1 (es)
EC (1) ECSP055804A (es)
ES (1) ES2282727T3 (es)
HR (1) HRP20050466A2 (es)
MX (1) MXPA05005393A (es)
PE (1) PE20040697A1 (es)
PL (1) PL375503A1 (es)
RS (1) RS20050390A (es)
TW (1) TW200500330A (es)
UY (1) UY28095A1 (es)
WO (1) WO2004047824A1 (es)
ZA (1) ZA200502410B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1916994T3 (pl) * 2004-06-29 2014-05-30 Takeda Pharma As Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku
JP7373191B2 (ja) 2017-05-12 2023-11-02 国立研究開発法人理化学研究所 クラスａ ｇｐｃｒ結合性化合物改変体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4424713A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Substituierte Benzamidine, ihre Herstellung und Verwendung als Arnzneistoffe
WO1996041645A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
DE19546452A1 (de) * 1995-12-13 1997-06-19 Boehringer Ingelheim Kg Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel
PT880362E (pt) * 1996-02-13 2005-10-31 Searle & Co Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4
DE19636689A1 (de) * 1996-09-10 1998-03-12 Boehringer Ingelheim Kg Neue Benzamidinderivate
US6197753B1 (en) * 1997-09-10 2001-03-06 Boehringer Ingelheim Kg Pyranoside derivatives
US6291531B1 (en) * 1999-10-07 2001-09-18 Boehringer Ingelheim Pharma Kg LTB4 antagonist, processes for the preparation thereof and its use as a pharmaceutical composition
US6417382B2 (en) * 2000-01-12 2002-07-09 Boehringer Ingelheim Pharma Kg Process for preparing aryl-iminomethyl-carbamino acid esters
TWI256305B (en) * 2000-08-18 2006-06-11 Pharmacia Corp Oral fast-melt pharmaceutical composition of a cyclooxygenase-2 inhibitor and process for preparing the same
WO2002055065A2 (en) * 2001-01-16 2002-07-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes
US20030119901A1 (en) * 2001-07-14 2003-06-26 Boehringer Ingelheim Pharma Kg Pharmaceutical formulation containing an LTB4 antagonist
BR0211090A (pt) * 2001-07-14 2004-06-15 Boehringer Ingelheim Pharma Formulação farmacêutica que contém um antagonista de ltb4

Also Published As

Publication number Publication date
EP1572179B1 (en) 2007-02-28
CA2506948A1 (en) 2004-06-10
DE60312215D1 (de) 2007-04-12
ATE355055T1 (de) 2006-03-15
KR20050086820A (ko) 2005-08-30
PE20040697A1 (es) 2004-11-22
ZA200502410B (en) 2005-10-03
AU2003298121A1 (en) 2004-06-18
TW200500330A (en) 2005-01-01
PL375503A1 (en) 2005-11-28
BR0316486A (pt) 2005-10-11
CO5580753A2 (es) 2005-11-30
DE60312215T2 (de) 2007-06-28
JP2006508992A (ja) 2006-03-16
US20040116516A1 (en) 2004-06-17
EP1572179A1 (en) 2005-09-14
RS20050390A (en) 2008-04-04
WO2004047824A1 (en) 2004-06-10
MXPA05005393A (es) 2005-08-03
UY28095A1 (es) 2004-06-30
EA200500860A1 (ru) 2005-12-29
ES2282727T3 (es) 2007-10-16
CN1717228A (zh) 2006-01-04
HRP20050466A2 (en) 2006-07-31

Similar Documents

Publication Publication Date Title
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA03005464A (es) Agentes antivirales.
SE0001899D0 (sv) New compounds
SE9900961D0 (sv) Novel compounds
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
UA83832C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение
SE0303480D0 (sv) Benzofuranes
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EA200500671A1 (ru) Фармацевтический состав оланзапина
ECSP055804A (es) Composición farmacéutica
TW200510370A (en) Urea derivatives
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2005035500A3 (en) Therapeutic agents useful for treating pain
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases